Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 3
1996 1
1997 2
1998 1
1999 2
2001 2
2002 1
2003 1
2004 2
2005 1
2006 1
2007 4
2008 1
2009 2
2011 2
2012 3
2013 1
2014 1
2015 2
2016 4
2017 3
2018 2
2019 2
2020 5
2021 7
2022 3
2023 1
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Gautret P, et al. Among authors: giordanengo v. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20. Int J Antimicrob Agents. 2020. Retraction in: Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416. PMID: 32205204 Free PMC article. Retracted. Clinical Trial.
Retraction notice to "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial" [International Journal of Antimicrobial Agents 56 (2020), 105949].
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Gautret P, et al. Among authors: giordanengo v. Int J Antimicrob Agents. 2025 Jan;65(1):107416. doi: 10.1016/j.ijantimicag.2024.107416. Epub 2024 Dec 26. Int J Antimicrob Agents. 2025. PMID: 39730229 Free PMC article. No abstract available.
RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activation.
Doye A, Chaintreuil P, Lagresle-Peyrou C, Batistic L, Marion V, Munro P, Loubatier C, Chirara R, Sorel N, Bessot B, Bronnec P, Contenti J, Courjon J, Giordanengo V, Jacquel A, Barbry P, Couralet M, Aladjidi N, Fischer A, Cavazzana M, Mallebranche C, Visvikis O, Kracker S, Moshous D, Verhoeyen E, Boyer L. Doye A, et al. Among authors: giordanengo v. J Exp Med. 2024 Oct 7;221(10):e20231562. doi: 10.1084/jem.20231562. Epub 2024 Aug 30. J Exp Med. 2024. PMID: 39212656 Free PMC article.
Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024.
de Prost N, Audureau E, Guillon A, Handala L, Préau S, Guigon A, Uhel F, Le Hingrat Q, Delamaire F, Grolhier C, Tamion F, Moisan A, Darreau C, Thomin J, Contou D, Henry A, Daix T, Hantz S, Saccheri C, Giordanengo V, Pham T, Chaghouri A, Bay P, Pawlotsky JM, Fourati S; SEVARVIR investigators. de Prost N, et al. Among authors: giordanengo v. Ann Intensive Care. 2024 Jun 28;14(1):101. doi: 10.1186/s13613-024-01319-w. Ann Intensive Care. 2024. PMID: 38940865 Free PMC article.
COVID-19 associated pulmonary aspergillosis in critically-ill patients: a prospective multicenter study in the era of Delta and Omicron variants.
Bay P, Audureau E, Préau S, Favory R, Guigon A, Heming N, Gault E, Pham T, Chaghouri A, Turpin M, Morand-Joubert L, Jochmans S, Pitsch A, Meireles S, Contou D, Henry A, Joseph A, Chaix ML, Uhel F, Roux D, Descamps D, Emery M, Garcia-Sanchez C, Levy D, Burrel S, Mayaux J, Kimmoun A, Hartard C, Pène F, Rozenberg F, Gaudry S, Brichler S, Guillon A, Handala L, Tamion F, Moisan A, Daix T, Hantz S, Delamaire F, Thibault V, Souweine B, Henquell C, Picard L, Botterel F, Rodriguez C, Dessap AM, Pawlotsky JM, Fourati S, de Prost N; SEVARVIR investigators. Bay P, et al. Ann Intensive Care. 2024 Apr 24;14(1):65. doi: 10.1186/s13613-024-01296-0. Ann Intensive Care. 2024. PMID: 38658426 Free PMC article.
Heterogeneous NLRP3 inflammasome signature in circulating myeloid cells as a biomarker of COVID-19 severity.
Courjon J, Dufies O, Robert A, Bailly L, Torre C, Chirio D, Contenti J, Vitale S, Loubatier C, Doye A, Pomares-Estran C, Gonfrier G, Lotte R, Munro P, Visvikis O, Dellamonica J, Giordanengo V, Carles M, Yvan-Charvet L, Ivanov S, Auberger P, Jacquel A, Boyer L. Courjon J, et al. Among authors: giordanengo v. Blood Adv. 2021 Mar 9;5(5):1523-1534. doi: 10.1182/bloodadvances.2020003918. Blood Adv. 2021. PMID: 33683342 Free PMC article.
Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic.
Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C, Giordanengo V, Gonfrier G, Raimondi V, Bausset O, Adjtoutah Z, Garnier M, Burel-Vandenbos F, Dadone-Montaudié B, Fassbender V, Palladini A, Courjon J, Mondain V, Contenti J, Dellamonica J, Leftheriotis G, Passeron T. Hubiche T, et al. Among authors: giordanengo v. JAMA Dermatol. 2021 Feb 1;157(2):202-206. doi: 10.1001/jamadermatol.2020.4324. JAMA Dermatol. 2021. PMID: 33237291 Free PMC article.
62 results